Biomaterials/tissue interactions: Possible solutions to overcome foreign body response

AAPS Journal

Volumn 12, Issue 2, 2010, Pages 188-196

  Morais, Jacqueline M ^a   Papadimitrakopoulos, Fotios ^a   Burgess, Diane J ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Biocompatible coating for implantable devices; Drug device combination products; Foreign body response (FBR); Glucose biosensor; Tissue compatibility assessment

Indexed keywords

ANGIOGENIC FACTOR; BIOMATERIAL; CORTICOSTEROID; DEXAMETHASONE; GLUCOCORTICOID; GLUCOSE; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID; VASCULOTROPIN;

ANALYTIC METHOD; ANGIOGENESIS; BIOCOMPATIBILITY; BIOSAFETY; BIOSENSOR; BLOOD GLUCOSE MONITORING; CELL CULTURE; CELL DIVISION; CELL GROWTH; CHEMICAL COMPOSITION; CONCENTRATION (PARAMETERS); FOREIGN BODY REACTION; HISTOCOMPATIBILITY; HUMAN; HYDROGEL; IMMUNE RESPONSE; IMPLANTATION; IN VITRO STUDY; IN VIVO STUDY; MATERIAL COATING; NONHUMAN; REVIEW; TISSUE INTERACTION;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOCOMPATIBLE MATERIALS; BIOSENSING TECHNIQUES; BLOOD GLUCOSE; COATED MATERIALS, BIOCOMPATIBLE; DEXAMETHASONE; DRUG DELIVERY SYSTEMS; FOREIGN-BODY REACTION; HUMANS; HYDROGELS; MATERIALS TESTING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77950650326     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-010-9175-3     Document Type: Review

References (95)

1. Prokop A. Bioartificial organs in the twenty-first century: nanobiological devices. Ann NY Acad Sci. 2001;944:472-490 (Pubitemid 34053330)
2. Wilson GS, Zhang Y, Reach G, Moatti-Sirat D, Poitout V, Thévenot DR, et al. Progress toward the development of an implantable sensor for glucose. Clin Chem. 1992;38(9):1613-1617
3. Klonoff DC. Technological advances in the treatment of diabetes mellitus: better bioengineering begets benefits in glucose measurement, the artificial pancreas, and insulin delivery. Pediatr Endocrinol Rev. 2003;1(2):94-100.
4. Koschwanez HE, Reichert WM. In vitro, in vivo and post explantation testing of glucose-detecting biosensors: current methods and recommendations. Biomaterials. 2007;28(25):3687-3703
5. Bailey TS, ZisserHC,Garg SK.Reduction in hemoglobinA1Cwith real-time continuous glucose monitoring: results from a 12-week observational study. Diabetes Technol Ther. 2007;9(3):203-210
6. Buckingham B, Caswell K, Wilson DM. Real-time continuous glucose monitoring. Curr Opin Endocrinol Diabetes Obes. 2007;14(4):288-295 (Pubitemid 47067113)
7. Callahan 4th TD, Natale A. Catheter ablation of atrial fibrillation. Med Clin North Am. 2008;92(1):179-201. xii. (Pubitemid 350176579)
8. Black MM, Drury PJ. Mechanical and other problems of artificial valves. Curr Top Pathol. 1994;86:127-159
9. Salgado AJ, Coutinho OP, Reis RL. Bone tissue engineering: state of the art and future trends. Macromol Biosci. 2004;4 (8):743-765 (Pubitemid 39257140)
10. Matsumoto T, Okazaki M, Nakahira A, Sasaki J, Egusa H, Sohmura T. Modification of apatite materials for bone tissue engineering and drug delivery carriers. Curr Med Chem. 2007;14 (25):2726-2733 (Pubitemid 350048326)
11. Kipshidze NN, Tsapenko MV, Leon MB, Stone GW, Moses JW. Update on drug-eluting coronary stents. Expert Rev Cardiovasc Ther. 2005;3(5):953-968
12. Williams DF. Tissue-biomaterial interactions. J Mater Sci. 1987;22:3421-3445
13. Laurencin CT, Elgendy H. The biocompatibility and toxicity of degradable polymeric materials: implication for drug delivery. In: Domb A, Maniar M, editors. Site specific drug delivery. New York: Wiley; 1994. p. 27-46.
14. Anderson JM. Biological responses to materials. Annu Rev Mater Res. 2001;31:81-110.
15. Fournier E, Passirani C, Montero-Menei CN, Benoit JP. Biocompatibility of implantable synthetic polymeric drug carriers: focus on brain biocompatibility. Biomaterials. 2003;24(19):3311-3331 (Pubitemid 36577679)
16. Arshady R. Polymeric biomaterials: chemistry, concepts, criteria. In: Arshady R, editor. Introduction to polymeric biomaterials: the polymeric biomaterials series. London: Citus Books; 2003. p. 1-62.
17. Ratner BA, Horbett TA. Some background concepts. In: Ratner BD, Schoen FJ, Lemons JE, editors. Biomaterials science: an introduction to materials in medicine. 2nd ed. San Diego: Elsevier; 2004. p. 237.
18. Anderson JM. Inflammatory response to implants. ASAIO Trans. 1988;34(2):101-107
19. Ziats NP,MillerKM,Anderson JM. In vitro and in vivo interactions of cells with biomaterials. Biomaterials. 1988;9(1):5-13. (Pubitemid 18035328)
20. Pappas N. An introduction to materials in medicine. Biomaterials science. New York: Academic; 1996. p. 60-64
21. Schoen FJ, Anderson JM. Host response to biomaterials and their evaluation. In: Ratner BD, Schoen FJ, Lemons JE, editors. Biomaterials science: an introduction to materials in medicine, 2nd. San Diego: Elsevier; 2004. p. 293-296
22. Sieminski AL, Gooch KJ. Biomaterial-microvasculature interactions. Biomaterials. 2000;21(22):2232-2241
23. Mitchell RN, Cotran RS. Acute and chronic inflammation in Robbins basic pathology. Philadelphia: Saunders; 2002. p. 33-60.
24. Ratner BD, Bryant SJ. Biomaterials: where we have been and where we are going. Annu Rev Biomed Eng. 2004;6:41-75. (Pubitemid 39209492)
25. Jutila MA. Leukocyte traffic to sites of inflammation. APMIS. 1992;100(3):191-201.
26. Pober JS, Cotran RS. The role of endothelial cells in inflammation. Transplantation. 1990;50(4):537-544
27. Williams GT, Williams WJ. Granulomatous inflammation-a review. J Clin Pathol. 1983;36(7):723-773
28. Wahl SM,WongH,McCartney-FrancisN. Role of growth factors in inflammation and repair. J Cell Biochem. 1989;40(2):193-199 (Pubitemid 19167269)
29. Johnston Jr RB. Current concepts: immunology, monocytes and macrophages. N Engl J Med. 1988;318(12):747-752 (Pubitemid 18090257)
30. Kovacs EJ. Fibrogenic cytokines: the role of immune mediators in the development of scar tissue. Immunol Today. 1991;12(1):17-23.
31. Pierce GF, Mustoe TA, Altrock BW, Deuel TF, Thomason A. Role of platelet-derived growth factor in wound healing. J Cell Biochem. 1991;45(4):319-326
32. Labat-Robert J, Bihari-Varga M, Robert L. Extracellular matrix. FEBS Lett. 1990;268(2):386-393 (Pubitemid 20241348)
33. Anderson JM, Langone JJ. Issues and perspectives on the biocompatibility and immunotoxicity evaluation of implanted controlled release systems. J Control Release. 1999;57(2):107-113
34. Mikos AG, McIntire LV, Anderson JM, Babensee JE. Host response to tissue engineered devices. Adv Drug Deliv Rev. 1998;33(1-2):111-139
35. Saad B, Abu-Hijleh G, Suter UW. Polymer biocompatibility assessment by cell culture techniques. In: Arshady R, editor. Introduction to polymeric biomaterials: the polymeric biomaterials series. London: Citus Books; 2003. p. 263-299
36. Ratner BD, Northup SJ, Anderson JM. Biological testing of biomaterials. In: Ratner BD, Schoen FJ, Lemons JE, editors. Biomaterials science: an introduction to materials in medicine. 2nd ed. San Diego: Elsevier; 2004. p. 355-360
37. Dekker A, Panfil C, Valdor M, Richter H, Mittermayer Ch, Kirkpatrick CJ. Quantitative methods for in vitro cytotoxicity testing of biomaterials. Cells Mater. 1994;4:101-112
38. Kirkpatrick CJ, Bittinger F, Wagner M, Köhler H, van Kooten TG, Klein CL, et al. Current trends in biocompatibility testing. Proc Inst Mech Eng [H]. 1998;212(2):75-84. (Pubitemid 128769984)
39. Royals MA, Fujita SM, Yewey GL, Rodriguez J, Schultheiss PC, Dunn RL. Biocompatibility of a biodegradable in situ forming implant system in rhesus monkeys. J Biomed Mater Res. 1999;45 (3):231-239 (Pubitemid 29165939)
40. ISO 10,933. Biological evaluation of medical devices. Geneva: International Standards Organizations; 1992.
41. Association for the Advancement of Medical Instrumentation. AAMI standards and recommended practices. Biological evaluation of medical devices, v.4., Suppl. Arlington: AAMI; 1997.
42. FDA. Blue Book Memorandum G95-1: FDA-modified version of ISO10, 933-part 1, biological evaluation of medical devices. Silver Spring: FDA; 1996.
43. US Pharmacopeia. Biological reactivity tests in vitro. In: US Pharmacopeia XXIII, editor. United States Pharmacopeial Convention, Inc., Rockville, MD, v.27. Rockville: US Pharmacopeia; 1995. p. 2173-2175
44. Hoffman AS, Cooper SL, Visser SA, Hergenrother RW, Lamba NMK, Peppas NA, et al. Classes of materials used in medicine. In: Ratner BD, Schoen FJ, Lemons JE, editors. Biomaterials science: an introduction to materials in medicine. 2nd ed. San Diego: Elsevier; 2004. p. 67-127.
45. Göpferich A. Polymer degradation and erosion: mechanisms and applications. Eur J Pharm Biopharm. 1996;42(1):1-11. (Pubitemid 26092502)
46. Shastri VP. Non-degradable biocompatible polymers in medicine: past, present and future. Current Pharm Biotech. 2003;4:331-337
47. Wisniewski N, Reichert M. Methods for reducing biosensor membrane biofouling. Colloids Surf B Biointerfaces. 2000;18(3-4):197-219. (Pubitemid 30479863)
48. Shen M, Horbett TA. The effects of surface chemistry and adsorbed proteins on monocyte /macrophage adhesion to chemically modified polystyrene surfaces. J Biomed Mater Res. 2001;57(3):336-345 (Pubitemid 32885265)
49. Dalsin JL, Hu BH, Lee BP, Messersmith PB. Mussel adhesive protein mimetic polymers for the preparation of nonfouling surfaces. J Am Chem Soc. 2003;125(14):4253-4258
50. de Vos P, Hoogmoed CG, Busscher HJ. Chemistry and biocompatibility of alginate-PLL capsules for immunoprotection of mammalian cells. J Biomed Mater Res. 2002;60(2):252-259 (Pubitemid 34194586)
51. Uchegbu IF, Schätzlein AG, Tetley L, Gray AI, Sludden J, Siddique S, et al. Polymeric chitosan-based vesicles for drug delivery. J Pharm Pharmacol. 1998;50(5):453-458 (Pubitemid 28241130)
52. Borchard G, Junginger HE. Modern drug delivery applications of chitosan. Adv Drug Deliv Rev. 2001;52(2):103. (Pubitemid 33079165)
53. Sano A, Hojo T, Maeda M, Fujioka K. Protein release from collagen matrices. Adv Drug Deliv Rev. 1998;31(3):247-266 (Pubitemid 28191868)
54. Geiger M, Li RH, Friess W. Collagen sponges for bone regeneration with rhBMP-2. Adv Drug Deliv Rev. 2003;55 (12):1613-1629 (Pubitemid 37420006)
55. Draye JP, Delaey B, van de Voorde A, van Den Bulcke A, de Reu B, Schacht E. In vitro and in vivo biocompatibility of dextran dialdehyde cross-linked gelatin hydrogel films. Biomaterials. 1998;19(18):1677-1687 (Pubitemid 28512848)
56. Vercruysse KP, Prestwich GD. Hyaluronate derivatives in drug delivery. Crit Rev Ther Drug Carrier Syst. 1998;15(5):513-555
57. Athanasiou KA, Niederauer GG, Agrawal CM. Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. Biomaterials. 1996;17(2):93-102.
58. Shive MS, Anderson JM. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Delivery Rev. 1997;28 (1):5-24.
59. Quinn CP, Pathak CP, Heller A, Hubbell JA. Photo-crosslinked copolymers of 2-hydroxyethyl methacrylate, poly(ethylene glycol) tetra-acrylate and ethylene dimethacrylate for improving biocompatibility of biosensors. Biomaterials. 1995;16(5):389-396
60. Espadas-Torre C, Meyerhoff ME. Thrombogenic properties of untreated and poly(ethylene oxide)-modified polymeric matrices useful for preparing intra-arterial ion-selective electrodes. Anal Chem. 1995;67(18):3108-3114
61. Paradossi G, Cavalieri F, Chiessi E, Spagnoli C, Cowman MK. Poly(vinyl alcohol) as versatile biomaterial for potential biomedical applications. J Mater Sci Mater Med. 2003;14(8):687-691 (Pubitemid 36976216)
62. Maruoka S, Matsuura T, Kawasaki K, Okamoto M, Yoshiaki H, Kodama M, et al. Biocompatibility of poly-vinyl-alcohol gel as a vitreous substitute. Curr Eye Res. 2006;31(7-8):599-606. (Pubitemid 44179986)
63. Kost J, Langer R. Equilibrium swollen hydrogels in controlled release applications. In: Peppas NA, editor. Hydrogels in medicine and pharmacy, v.3. Boca Raton: CRC; 1997. p. 95-108.
64. Ravin AG, Olbrich KC, Levin LS, Usala AL, Klizman B. Longand short-term effects of biological hydrogels on capsule microvascular density around implants in rats. J Biomed Mater Res. 2001;58:313-318
65. Quinn CA, Connor RE, Heller A. Biocompatible, glucosepermeable hydrogel for in situ coating of implantable biosensors. Biomaterials. 1997;18(24):1665-1670 (Pubitemid 28185067)
66. Hickey T, Kreutzer D, Burgess DJ, Moussy F. In vivo evaluation of a dexamethasone/PLGA microsphere system designed to suppress the inflammatory tissue response to implantable medical devices. J Biomed Mater Res. 2002;61(2):180-187 (Pubitemid 34602364)
67. Patil SD, Papadimitrakopoulos F, Burgess DJ. Dexamethasoneloaded poly(lactic-co-glycolic) acid microspheres/poly(vinyl alcohol) hydrogel composite coatings for inflammation control. Diabetes Technol Ther. 2004;6(6):887-897 (Pubitemid 40129338)
68. Galeska I, Kim TK, Patil SD, Bhardwaj U, Chatttopadhyay D, Papadimitrakopoulos F, et al. Controlled release of dexamethasone from PLGA microspheres embedded within polyacidcontaining PVA hydrogels. AAPS J. 2005;7(1):E231-40. (Pubitemid 41554285)
69. Norton LW, Tegnell E, Topored SS, Reichert WM. In vitro characterization of vascular endothelial growth factor and dexamethasone releasing hydrogels for implantable probe coatings. Biomaterials. 2005;26(16):3285-3297 (Pubitemid 39647262)
70. Norton LW, Koschwanez HE, Wisniewski NA, Klitzman B, Reichert WM. Vascular endothelial grown factor and dexamethasone release from non-fouling sensor coating affect the foreign body response. J Bio Mater Res A. 2007;81(4):858-869 (Pubitemid 46835081)
71. Patil SD, Papadimitrakopouos F, Burgess DJ. Concurrent delivery of dexamethasone and VEGF for localized inflammation control and angiogenesis. J Control Release. 2007;117:68-79.
72. Bhardwaj U, Sura R, Papadimitrakopoulos F, Burgess DJ. Controlling acute inflammation with fast releasing dexamethasone-PLGA microsphere/PVA hydrogel composites for implantable devices. Diabetes Sci Technol. 2007;1(1):8-17.
73. Bhardwaj U, Radhacirsshana S, Papadimitrakopoulos F, Burgess DJ. PLGA/PVA hydrogel composites for long-term inflammation control following s.c. implantation. Int J Pham. 2010;484:78-86.
74. Perreti M, Ahluwalia A. The microcirculation and inflammation: site of action for glucocorticoids. Microcirculation. 2000;7:147-161
75. Strecker EP, Gabelmann A, Boos I, Lucas C, Xu Z, Haberstroh J, et al. Effect on intimal hyperplasia of dexamethasone released from coated metal stents compared with non-coated stents in canine femoral arteries. Cardiovasc Intervent Radiol. 1998;21 (6):487-496 (Pubitemid 28531499)
76. Ronneberger B, Kissel T, Anderson JM. Biocompatibility of ABA triblock copolymer microparticles consisting of poly(Llactic-co-glycolic-acid) A-blocks attached to central poly(oxyethylene) B-blocks in rats after intramuscular injection. Eur J Pharm Biopharm. 1997;43:19-28. (Pubitemid 28298806)
77. Daugherty AL, Cleland JL, Duenas EM, Mrsny RJ. Pharmacological modulation of the tissue response to implanted polylacticco-glycolic acid microspheres. Eur J Pharm Biopharm. 1997;44 (1):89-102.
78. Lunsford L, McKeever U, Eckstein V, Hedley ML. Tissue distribution and persistence in mice of plasmid DNA encapsulated in a PLGA-based microsphere delivery vehicle. J Drug Target. 2000;8(1):39-50. (Pubitemid 30189692)
79. Hickey T, Kreutzer D, Burgess DJ, Moussy F. Dexamethasone/ PLGAmicrospheres for continuous delivery of an anti-inflammatory drug for implantable medical devices. Biomaterials. 2002;23: 1649-1656 (Pubitemid 34158587)
80. Kyrolainen M, Rigsby P, Eddy S, Vadgama P. Bio-/hemocompatibility: implications and outcomes for sensors? Acta Anaesthesiol Scand Suppl. 1995;104:55-60.
81. Gerritsen M, Jansen JA, Kros A, Vriezema DM, Sommerdijk NA, Nolte RJ, et al. Influence of inflammatory cells and serum on the performance of implantable glucose sensors. J Biomed Mater Res. 2001;54(1):69-75.
82. Tanihara M, Suzuki Y, Yamamoto E, Noguchi A, Mizushima Y. Sustained release of basic fibroblast growth factor and angiogenesis in a novel covalently cross-linked gel of heparin and alginate. J Biomed Mater Res. 2001;56:216-221 (Pubitemid 32520696)
83. Ward WK, Quinn MJ, Wood MD, Tiekotter KL, Pidikiti S, Gallagher JA. Vascularizing the tissue surrounding a model biosensor: how localized is the effect of a subcutaneous infusion of vascular endothelial growth factor (VEGF)? Biosens Bioelectron. 2003;19:155-163 (Pubitemid 37377963)
84. Kedem A, Perets A, Gamlieli-Bonshtein I, Dvir-Ginzberg M, Mizrahi S, Cohen S. Vascular endothelial growth factor-releasing enhance vascularization and engraftment of hepatocytes transplanted on liver lobes. Tissue Eng. 2005;11:715-722 (Pubitemid 40960776)
85. Gaytan F, Morales C, Bellido C, Sanchez-Criado JE. Selective apoptosis of luteal endothelial cells in dexamethasone-treated rats leads to ischemic necrosis of luteal tissue. Biol Reprod. 2002;66:232-240 (Pubitemid 34020607)
86. Halaby IA, Lyden SP, Davies MG, Roztocil E, Salamone LJ, Brooks AI. Glucocorticoid-regulated VEGF expression in ischemic skeletal muscle. Molec Ther. 2002;5(3):300-306 (Pubitemid 34213250)
87. Reach G, Wilson GS. Can continuous glucose monitoring be used for the treatment of diabetes? Anal Chem. 1992;64 (6):381A-6.
88. Rebrin K, Fischer U, Hahn von Dorsche H, von Woetke T, Abel P, Brunstein E. Subcutaneous glucose monitoring by means of electrochemical sensors: fiction or reality. J Biomed Eng. 1992;14 (1):33-40.
89. Bobbioni-Harsch E, Rohner-Jeanrenaud F, Koudelka M, de Rooij N, Jeanrenaud B. Lifespan of subcutaneous glucose sensors and their performances during dynamic glycemia changes in rats. J Biomed Eng. 1993;15(6):457-463 (Pubitemid 23312064)
90. Gilligan BJ, Shults MC, Rhodes RK, Updike SJ. Evaluation of a subcutaneous glucose sensor out to 3 months in a dog model. Diabetes Care. 1994;17(8):882-887
91. Gerritsen M, Kros A, Srpakel V, Lutterman JA, Notle RJM, Jansen JA. Biocompatibility evaluation of sol-gel coating for subcutaneously implantable glucose sensors. Biomaterials. 2000;21:71-78
92. Yu B, Wang C, Ju YM, West L, Harmon J, Moussy Y, et al. Use of hydrogel coating to improve the performance of implanted glucose sensors. Biosens Bioelectron. 2008;23(8):1278-1284
93. Wilson GS, Gifford R. Biosensors for real-time measurements in vivo. Biosens Bioelectron. 2005;20:2388-2403
94. Rigby G, Ahmed S, Horseman G, Vadgama P. In vivo glucose monitoring with open microflow-influences of fluid composition and preliminary evaluation in man. Anal Chim Acta. 1999;385:23-32. (Pubitemid 29131526)
95. Bhardwaj U, Papadimitrakopoulos F, Burgess DJ. A review of the development of a vehicle for localized and controlled drug delivery for implantable biosensors. J Diabetes Sci Tech. 2008;2 (6):1016-1029